Efficacy and safety of papaverine hydrochloride injection combined with Alteplase intravenous thrombolysis in the treatment of acute cerebral infarction<4.5 h
Objective:To analyze the therapeutic effect of papaverine hydrochloride injection combined with alteplase arterial thrombolysis on acute cerebral infarction<4.5 hours.Methods:The clinical data of 81 patients with acute cerebral infarction who underwent surgical treatment in our hospital from August 2022 to August 2023 were retrospectively collected.According to different treatment plans,the patients were divided into control group(38 cases)and observation group(43 cases).The neurological function(NIHSS),clinical efficacy(CGI),self-care ability(modified Barthel Index)and safety of the two groups were analyzed and compared.Results:The NHISS score of both groups after treatment was significantly lower than that before treatment,and the NHISS score of the observation group was significantly greater than that of the control group(P<0.05).After treatment,SI scores of both groups were significantly decreased,GI and EI scores were significantly increased,and the changes of scores in the observation group were significantly greater than those in the control group(P<0.05).After treatment,the Barthel score of both groups was significantly increased,and the Barthel score of the observation group was significantly higher than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Papaverine hydrochloride injection combined with alteplase arterial thrombolysis in the treatment of acute cerebral infarction patients with onset time<4.5 hours can improve the neurological function of patients,improve clinical efficacy and self-care ability,and have high safety.
万方数据
